Description
GDC-0623 is an inhibitor of MEK that prevents MEK-dependent B-Raf and KRAS signaling. GDC-0623 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for several cancers.
Product Unit Size | Cost | Quantity | Stock |
---|
GDC-0623 is an inhibitor of MEK that prevents MEK-dependent B-Raf and KRAS signaling. GDC-0623 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for several cancers.
Cas No. | 1168091-68-6 |
---|---|
Purity | ≥98% |
Formula | C16H14FIN4O3 |
Formula Wt. | 456.21 |
IUPAC Name | 5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide |
Solubility | DMSO 91 mg/mL warmed (199.46 mM) Ethanol 5 mg/mL warmed (10.95 mM) Water Insoluble |
Appearance | Beige Powder |
Store Temp | 4°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet | |
Brochures |
Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013 Sep 12;501(7466):232-6. PMID: 23934108.
SARS-CoV-2 inhibitor
Synthetic steroid hormone; AR agonist, ER and P...
PARP inhibitor; potential Pim1 inhibitor.
Anthracycline, DNA intercalator; topoisomerase ...
Everolimus impurity
Fatty acid found in dairy products; HDAC inhibi...
Dual kinase and GTPase inhibitor.
Statin; HMG-CoA reductase inhibitor, potential ...
Viral M2 proton channel blocker, MAO-A, NET, NM...
Dual inhibitor of p70S6K and Akt.
Nitroimidazole, binds DNA; nucleic acid synthes...
Imidazole; PPARγ agonist, RORγ inverse agonis...
D-amino acid, incorporated into bacterial cell ...
Pneumonia antigen
Nucleoside (thymidine) analog; DNA chain termin...
Oltipraz analog, salivary gland secretion enhan...
Voltage-gated Na+ channel blocker, mAChR antago...
Dihydropyridine; L-type and N-type Ca2+ channel...
Fluoroquinolone; topoisomerase IV and bacterial...
Type A trichothecene mycotoxin produced by Fusa...